Print version ISSN 1516-3180
Sao Paulo Med. J. vol.124 no.5 São Paulo 2006
Revisão sistemática no manejo clínico de disfunções sexuais induzidas por antipsicóticos na esquizofrenia
Anna Maria Niccolai Costa; Mauricio Silva de Lima; Jair de Jesus Mari
Universidade Federal de São Paulo, São Paulo, Brazil
INTRODUCTION: Sexual dysfunction frequently occurs in patients with schizophrenia under antipsychotic therapy, and the presence of sexual side effects may affect compliance. The aim of this study was to review and describe clinical findings relating to the appropriate management of such dysfunctions.
MATERIAL AND METHODS: The research was carried out through Medline (from 1966 to March 2005), PsycInfo (from 1974 to March 2005), and Cochrane Library (from 1965 to March 2005) and included any kind of study, from case reports to randomized trials.
RESULTS: The most common sexual dysfunctions found in the literature were libido decrease, difficulties in achieving and maintaining erection, ejaculatory dysfunction, orgasmic dysfunction, and menstrual irregularities. Thirteen papers were found: eight of them were open-label studies, four were descriptions of cases, and only one was a randomized clinical trial. All of them were short-term and had small sample sizes. The agents used were: bromocriptine, cabergoline, cyproheptadine, amantadine, shakuyaku-kanzo-to, sildenafil and selegiline.
DISCUSSION: There was no evidence that those agents had proper efficacy in treating the antipsychotic-induced sexual dysfunction. An algorithm for managing sexual dysfunction induced by antipsychotics is suggested as a support for clinical decisions. Since the outcome from schizophrenia treatment is strongly related to compliance with the antipsychotics, prevention of sexual dysfunction is better than its treatment, since there is a scarcity of data available regarding the efficacy of intervention to deal with these problems.
Key words: Schizophrenia. Antipsychotic agents. Sexual and gender disorders. Libido.
INTRODUÇÃO: Disfunção sexual freqüentemente ocorre em pacientes com esquizofrenia em terapia com antipsicóticos e a presença de efeitos adversos sexuais pode afetar a adesão ao tratamento. O objetivo do estudo é rever e descrever achados clínicos relacionados ao manejo apropriado de tais disfunções.
MATERIAIS E MÉTODOS: A pesquisa foi feita pelo Medline (de 1966 a março de 2005), PsycInfo (de 1974 a março de 2005) e Biblioteca Cochrane (de 1965 a março de 2005) e incluiu qualquer tipo de desenho de estudo de relato de caso a estudos clínicos randomizados.
RESULTADOS: As disfunções sexuais mais comuns encontradas na literatura foram diminuição da libido, dificuldades em alcançar e manter ereção, disfunção ejaculatória, orgásmica e irregularidades menstruais. Treze artigos foram encontrados: oito deles eram estudos abertos, quatro descrições de casos e somente um estudo clínico randomizado. Todos eram de curta duração e com tamanho de amostra pequeno. Os agentes usados foram: bromocriptina, cabergolina, ciproheptadina, amantadina, shakuyaku-kanzo-to, sildenafil e selegilina.
DISCUSSÃO: Não há evidências de eficácia apropriada destes agentes no tratamento da disfunção sexual induzida por antipsicóticos. Um algoritmo foi sugerido para manejo da disfunção sexual induzida por antipsicóticos, suportando decisões clínicas. Como o desfecho da esquizofrenia é fortemente relacionado a adesão ao tratamento com antipsicóticos, a prevenção da disfunção sexual é melhor que seu tratamento, visto que muito poucos dados estão disponíveis sobre a eficácia de intervenções destes problemas.
Palavras-chave: Esquizofrenia. Agentes antipsicóticos. Transtornos sexuais e da identidade sexual. Libido.
Schizophrenia treatment needs to cover several psychological and psychosocial interventions, and pharmacological treatment is essential for stabilizing the disease course and decreasing relapses. It is expected that virtually all patients with confirmed diagnoses of schizophrenia will receive antipsychotic drugs throughout their lives, and the efficacy of antipsychotic drugs has been confirmed in a number of randomized controlled trials. However, such drugs may induce some side effects such as acute Parkinsonism, tardive dyskinesia and neuroleptic malignant syndrome.1-7
Sexual dysfunction is often not specifically evaluated in clinical studies. When it affects patients on drug therapy, it affects their self-esteem, causes trouble for their sexual partners, interferes with their quality of life and compromises treatment compliance.8 Sexual dysfunction can be an important source of distress for patients and is one of the factors that must be taken into account when antipsychotic and anticholinergic drugs are selected to treat extrapyramidal symptoms.9 For example, in one study, a questionnaire was answered by 41 patients with schizophrenia under antipsychotic treatment, and it was detected that, among all the adverse effects and symptoms relating to mental disorders, the most important were the genital/sexual effects, and particularly impotence.10
Another publication involving a case-control study on the rates of sexual dysfunction among patients with schizophrenia in comparison with the general population indicated that male patients reported less desire for sex. These patients were less likely to achieve and maintain an erection, were more prone to premature ejaculation, and were less satisfied with the intensity of their orgasms. Female patients, however, reported less enjoyment.11
Although a high number of patients desire sexual relations (36.6% of men and 36.9% of women), sexual dysfunction is often observed in this population: 21.5% of men complain of erectile dysfunction and 18.7% of ejaculatory dysfunction; 19.3% of women and 15.9% of men complain of orgasmic dysfunction.12 Besides, 21.7% of women experience gonadal dysfunction as amenorrhea.12
The aim of this study is to review and to describe clinical findings related to the appropriate management of such dysfunctions.
MATERIAL AND METHODS
A protocol for a systematic review was established in order to review the clinical management of antipsychotic-induced sexual dysfunctions in schizophrenia because of the importance of this subject in psychiatric clinical practice and its implications. The review was performed by seeking and selecting any studies related to this topic, from case reports to randomized clinical trials. The studies were located via electronic data sources, published citations and letters to authors. Reference searching was also added to the review.
Searches were performed in the following electronic databases: Medline (from 1966 to March 2005), PsycInfo (from 1974 to March 2005) and Cochrane Library (from 1965 to March 2005). For each database, studies were obtained and examined. The databases were searched using the following words: #1 - sexual OR erectile OR ejaculatory OR impotence OR menstrual OR hyperprolactinemia OR prolactin OR galactorrhea OR amenorrhea OR endocrine OR endocrinol*; #2 - dysfunct*; #3 - #1 and #2; #4 - antipsychotic* OR neuroleptic* OR dopamine; #5 - schizophren*; #6 - #4 and #5; and #7 - #3 and #6. The * symbol means that the beginning of the word was used (root term), allowing for the identification of more related terms.
The participants were individuals diagnosed with schizophrenia by any method of diagnosis. Those with schizoaffective disorder, schizophreniform disorder or psychotic illness were also included. All subjects were under treatment using either first or second antipsychotics. The study design was not taken into consideration since such a small number of studies were found. The clinical outcomes were those reported in the original studies on antipsychotic-related sexual dysfunction, and they included: erectile dysfunction, frigidity, anorgasmy, delayed ejaculation and other characteristics described in the studies.
The search resulted in 13 papers: eight were open-label studies, four were descriptions of cases and only one was a randomized clinical trial. All of them were short-term and had small sample sizes, as shown in Table 1.13-25 Bromocriptine was involved in the treatment of these dysfunctions in two studies, sildenafil in four, amantadine in two and cyproheptadine, imipramine, shakuyaku-kanzo-to, cabergoline and selegiline in one each.
All of the antipsychotics that induced sexual dysfunction and which are described in Table 1 are first-generation antipsychotics, except for risperidone and olanzapine.
Cyproheptadine, a 5HT2 antagonist with antihistaminergic and adrenolytic properties, has also been used to improve sexual function and anorgasmy caused by antidepressants when taken in doses of 4 mg four times per day.26 As previously mentioned, there is one report in the literature on the use of imipramine in low doses (25-50 mg per day) for thioridazine-induced orgasmic disorder; however, the mechanism of action is not clear.27
Amantadine causes dopamine release at neuronal terminals. In patients with schizophrenia, amantadine decreases prolactin levels secondary to treatment with an antipsychotic. Amantadine also seems to improve sexual function when taken in doses of 100 mg per day in male patients.19 Bromocriptine, a dopamine agonist when administered in doses of 2.5 mg two or three times per day, may improve the libido of patients with hyperprolactinemia, normalize the menstrual cycle in amenorrheic patients and increase serum testosterone levels.14 However, it can also exacerbate psychosis. Another dopamine agonist is cabergoline, at a dose of 0.5 mg twice a week. Dopamine agonists such as bromocriptine and cabergoline may be successful in reducing the level of hyperprolactinemia and alleviating symptoms in some patients.15
Previous studies14 have shown that modest doses of bromocriptine may be safely prescribed to patients taking older first-generation agents, and who have symptomatic hyperprolactinemia without exacerbating psychosis.
Only three case reports and one open-label trial mentioned the use of sildenafil in antipsychotic-induced dysfunction.20-23 These pharmacological strategies described above, once initiated, should not be discontinued until a minimum of two weeks of therapy have been administered.
Shakuyaku-kanzo-to (TJ-68) is a Japanese medicine that is composed of two herbs (Radix paeoniae and Radix glycyrrhizae) and has been used to treat acute muscle cramps including menstrual pains. TJ-68 has been investigated in relation to neuroleptic-induced hyper-prolactinemia. Although the mechanism is unknown, TJ-68 may have a direct inhibitory effect on prolactin release from the pituitary. Alternatively, the observed effect of TJ-68 may be explained by an indirect action when reducing estradiol.24,28
Selegiline is a selective monoamine oxidase-B inhibitor; in low doses it selectively inhibits the oxidation of dopamine and phenylethylamine.29 Its metabolites, L-amphetamine and L-methamphetamine, have sexual arousal properties.25 But in the only double-blind placebo-controlled trial found in the literature, selegiline did not show any effectiveness in improving sexual functioning, despite a significant decrease in prolactin levels.30
A description of the main drugs, respective doses, potential drug interactions and side effects can be found in Table 2.13-20,23,24,27,30-38
Sexual performance among patients with schizophrenia may differ from the qualitative and quantitative patterns in the normal population. It may be altered through three main factors: by the disease itself as a consequence of affective and/or cognitive impairment; by antipsychotic drugs; and by other clinical problems (such as diabetes, hypertension, alcohol and drug abuse).39,40- 43
In order to eliminate non-pharmacological factors, it is important to identify the factors that originated the sexual dysfunction, through evaluation of the patient's medical history and also physical and laboratory examinations. Both men and women should be asked specific questions regarding sexual dysfunction, and menstrual abnormalities should be evaluated during routine clinical evaluation. Furthermore, questions about dysfunction during autoerotic sexual activity (masturbation) and sexual intercourse are recommended in order to verify whether the dysfunction is provoked by the medication or by psychogenic causes.
After identifying the nature of the sexual dysfunction and its cause, it is important to evaluate the degree of patients' dissatisfaction and discomfort. The most common sexual disturbance is ejaculatory dysfunction induced by first-generation antipsychotics.44 Erectile dysfunction in males45 and loss of libido in both sexes have been documented among patients who use first-generation antipsychotics,46 including haloperidol, as well as among those who use second-generation antipsychotics (clozapine47 and risperidone48). Gonadal dysfunctions such as amenorrhea and galactorrhea can be found in these patients as well, and the estimated prevalence of amenorrhea in patients who use first-generation antipsychotics is from 15% to 50%,49 and 19% for galactorrhea.50 First-generation antipsychotics seem to create an increase in dose-dependent prolactin secretion51,52 and this effect suggests that is derived primarily from the pituitary.53
According to evidence relating to the use of serotonergic antidepressants, their influence on sexual function appear to be associated with decreased libido, erectile dysfunction and orgasmic dysfunction.54 Thus, the most likely explanation is that 5-HT2 receptor antagonism caused by second-generation antipsychotics may somehow contribute to the effect of prolactin elevation. These findings suggest that the specificity of second-generation antipsychotics, while presenting less dopamine receptor blockade in the tubularinfundibular system, may also exert a minor impact on prolactin levels.55
There are data suggesting that the incidence of sexual dysfunction differs according to the antipsychotic used. Second-generation antipsychotics have not been extensively studied with regard to sexual dysfunction, but they certainly differ from first-generation antipsychotics56 and also differ from each other.57-61 Several studies have shown an incidence of sexual dysfunction of 25-60% among patients treated with first-generation antipsychotics45,62,63 or with risperidone.57-59,64 24% of the patients treated with clozapine and 45% of the patients treated with first-generation antipsychotics present with one or more sexual side effects, including erectile and ejaculatory dysfunction.65 Studies have shown different results: Knegtering et al.57 found olanzapine-induced sexual dysfunction in 27% of their schizophrenic patients; Montejo et al.59 found it in 10-33%; and Bobes et al. found it in 35.3% of patients. Quetiapine induced a lower rate of sexual dysfunction (18.2%), and risperidone the highest rate (43.2%).60 Thus, the findings in the literature indicate that all second-generation antipsychotics except for risperidone induce lower rates of sexual dysfunction.66 However, most of the sexual function evaluation data was not obtained from longitudinal studies, and base data, treatment duration, disease onset and illness severity were not taken into consideration. More studies are needed in order to have a better and clearer understanding.
CONCLUSION AND RECOMMENDATIONS
Kaplan67 observed that several patients suffering from schizophrenia who presented with sexual dysfunction had sought sexual therapy prior to the onset of the psychotic phase of the disease. The author mentioned that sexual therapy should only be administered once it is certain that the illness is in a remission phase and that the sexual dysfunction is not drug-induced or a defense against a possible episode of illness. This author also expressed concern regarding the use of sexual therapy among subjects with sexual dysfunction, since the resolution of these symptoms may interrupt the homeostasis of the patient and ultimately cause a relapse. This risk should be evaluated on behalf of such patients and respective partners, and they should be provided with the necessary information, be advised to practice satisfactory sexual experiences and be warned against inappropriate behavior.
The aim of a systematic review is to thorou-ghly assess the best possible evidence about the effects of a healthcare intervention or treatment in a particular healthcare situation, by means of a set procedure. However, in this case, due to the lack of double-blind studies and the bias of non-publication of negative treatments and strategies, it is impossible to estimate the relative efficacy of the interventions available for treating antipsychotic-induced sexual dysfunction. In order to avoid iatrogenic sexual dysfunction in schizophrenia, patients should first be given the option of an appropriate drug, as discussed above. The patients who present higher risk of sexual disorders are those receiving first-generation antipsychotics and, more specifically, those taking high doses of these drugs (dose-dependent effect).68 In cases where a drug-induced sexual dysfunction is present, it is advisable to reduce first-generation antipsychotics to lower doses that are still effective, maintaining the clinical status. Moreover, if the patient can be maintained on a low dose, the incidence of other adverse symptoms that may interfere in sexual activity, such as sedation and Parkinsonism, will be reduced.
Withdrawal of a first-generation antipsychotic, or switching from a first-generation to a prolactin-sparing second-generation antipsychotic, should be done if hyperprolactinemia is present. Changes in antipsychotic input may also alter sexual function. If the dysfunction persists while the patient is receiving anticholinergics, the drug should be discontinued since there is evidence that anticholinergic properties found in some antidepressants can cause sexual dysfunction.69 Acetylcholine will probably not play a direct role in sexual function; however, it may be important in the adrenergic-cholinergic balance that is necessary for normal sexual function.70
Although the more favorable benefit-versus-risk ratio of the new antipsychotics represents a major improvement over the older neuroleptics, differences need to be addressed and more clearly documented. There was an almost complete lack of randomized controlled trials (RCTs) on the clinical management of antipsychotic-induced sexual dysfunction in the literature, and no proper comparisons of the efficacy of agents. Further clinical trials focusing on the sexual sphere are necessary in order to progress with regard to compliance and distress among patients with schizophrenia.
On the basis of the scarce data available, an attempt was made to design a preliminary algorithm for the clinical management of antipsychotic-induced sexual dysfunction, as described in Figure 1. It is important to point out that such an algorithm should be analyzed within the context of the patient's overall clinical condition, avoiding radical interventions that could threaten the patient's clinical stability.
In conclusion, the findings in the literature indicate that antipsychotics may have different profiles of adverse sexual effects, but the results are inconclusive since most of the sexual function evaluation was not performed in longitudinal studies. Moreover, base data, treatment duration, disease onset and illness severity were not taken into consideration.
Adverse sexual effects must be diagnosed, and should be discussed clearly and treated while maintaining the patient's mental status, treatment compliance and quality of life. More studies are needed in order to provide physicians with better understan-ding of this problem, thereby leading towards efficacious and safe solutions.
1. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2003;(1):CD001359. [ Links ]
2. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev. 2002;(3):CD001951. [ Links ]
3. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev. 2002;(2):CD001357. [ Links ]
4. Fenton M, Coutinho ES, Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2001;(3):CD000525. [ Links ]
5. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000;(4):CD001945. [ Links ]
6. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;(3):CD002306. [ Links ]
7. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2000;(3):CD000967. [ Links ]
8. Teusch L, Scherbaum N, Bohme H, Bender S, Eschmann-Mehl G, Gastpar M. Different patterns of sexual dysfunctions asso-ciated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry. 1995;28(3):84-92. [ Links ]
9. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull. 1997;23(4):567-82. [ Links ]
10. Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med. 1990;20(4):843-8. [ Links ]
11. Macdonald S, Halliday J, MacEWAN T, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry. 2003;182:50-6. [ Links ]
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. [ Links ]
13. Beau Y, Guillard P. Essai de traitement par la bromocriptine des effets secondaires endocriniens des traitements psychotropes. [Trial therapy with bromocriptine of secondary endocrine effects after psychotropic treatment]. Ann Med Psychol (Paris). 1980;138(2):179-86. [ Links ]
14. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol. 1986;40(4):639-46. [ Links ]
15. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000;23(11):765-70. [ Links ]
16. Jeffries JJ, Walker C. Cyproheptadine and drug-induced anorgasmia. Can J Psychiatry. 1987;32(1):79. [ Links ]
17. Aizenberg D, Shiloh R, Zemishlany Z, Weizman A. Low-dose imipramine for thioridazine-induced male orgasmic disorder. J Sex Marital Ther. 1996;22(3):225-9. [ Links ]
18. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7(2):91-5. [ Links ]
19. Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol. 1998;21(6):355-7. [ Links ]
20. Benatov R, Reznik I, Zemishlany Z. Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient. Eur Psychiatry. 1999;14(6):353-5. [ Links ]
21. Lare SB, Labbate LA. Sildenafil and erectile dysfunction. Am J Psychiatry. 2000;157(12):2055-6. [ Links ]
22. Atmaca M, Kuloglu M, Tezcan E. Sildenafil use in patients with olanzapine-induced erectile dysfunction. Int J Impot Res. 2002;14(6):547-9. [ Links ]
23. Aviv A, Shelef A, Weizman A. An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. J Clin Psychiatry. 2004;65(1):97-103. [ Links ]
24. Yamada K, Kanba S, Yagi G, Asai M. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. J Clin Psychopharmacol. 1997;17(3):234-5. [ Links ]
25. Angrist B, Gershon S. Clinical effects of amphetamine and L-DOPA on sexuality and aggression. Compr Psychiatry. 1976;17(6):715-22. [ Links ]
26. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995;18(4):320-4. [ Links ]
27. Siever LJ. The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. J Clin Psychopharmacol. 1981;1(1):2-7. [ Links ]
28. Yamada K, Kanba S, Yagi G, Asai M. Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J Clin Psychopharmacol. 1999;19(4):380-1. [ Links ]
29. Berry MD, Juorio AV, Paterson IA. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol. 1994;44(2):141-61. [ Links ]
30. Kodesh A, Weizman A, Aizenberg D, Hermesh H, Gelkopf M, Zemishlany Z. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin Neuropharmacol. 2003;26(4):193-5. [ Links ]
32. Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W. Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry. 1975;126:285-8. [ Links ]
33. Varia IM, Cavenar JO Jr, Taska RJ, Maltbie AA. Bromocriptine in the treatment of haloperidol-induced galactorrhea. N C Med J. 1982;43(11):769-70. [ Links ]
34. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med. 1992; 37(8):737-40. [ Links ]
35. Popli A, Gupta S, Rangwani SR. Risperidone-induced galactorrhea associated with a prolactin elevation. Ann Clin Psychiatry. 1998;10(1):31-3. [ Links ]
36. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11(4):435-40. [ Links ]
37. Blumenthal M, Busse WR, Goldberg A, et al. The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston: Integrative Medicine Communications; 1998. [ Links ]
38. Armanini D, Bonanni G, Palermo M. Reduction of serum testosterone in men by licorice. N Engl J Med. 1999;341(15):1158. [ Links ]
39. Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry. 2003;48(1):14-21. [ Links ]
40. Marinow A. Diabetes in chronic schizophrenia. Dis Nerv Syst. 1971;32(11):777-8. [ Links ]
41. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophreniaa preliminary study. J Clin Hosp Pharm. 1986;11(4):297-9. [ Links ]
42. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983;44(2):42-6. [ Links ]
43. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002;63(Suppl 9):5-11. [ Links ]
44. Blair JH, Simpson GM. Effect of antipsychotic drugs on reproductive functions. Dis Nerv Syst. 1966;27(10):645-7. [ Links ]
45. Kotin J, Wilbert DE, Verburg D, Soldinger SM. Thioridazine and sexual dysfunction. Am J Psychiatry. 1976;133(1):82-5. [ Links ]
46. Laughren TP, Brown WA, Petrucci JA. Effects of thioridazine on serum testosterone. Am J Psychiatry. 1978;135(8):982-4. [ Links ]
47. Schnieden H. Effect of psychoactive drugs on the motility of human spermatozoa. ICRS J Int Res Commun. 1974;2(5):1322. [ Links ]
48. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61. [ Links ]
49. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982;170(8):463-7. [ Links ]
50. Windgassen K, Wesselmann U, Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 1996;33(3):142-6. [ Links ]
51. Gruen PH, Sachar EJ, Langer G, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 1978;35(1):108-16. [ Links ]
52. Langer G, Sachar EJ, Gruen PH, Halpern FS. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature. 1977;266(5603):639-40. [ Links ]
53. Rubin RT. Prolactin and schizophrenia. In: Meltzer HY, Coyle JT, Kopin IJ, editors. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 803-6. [ Links ]
54. Harrison WM, Rabkin JG, Ehrhardt AA, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol. 1986;6(3):144-9. [ Links ]
55. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996;124(1-2):2-34. [ Links ]
56. Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry. 2001;62(7):541-4. [ Links ]
57. Knegtering H, Blijd C, Boks M. Sexual dysfunction and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr Res. 1999;36(1-3):355-6. [abstract]. [ Links ]
58. David S, Crawford AM, Breier A. Prolactin levels in olanzapine versus typical and atypical antipsychotics. Schizophr Res. 1998;29(1-2):153. [abstract]. [ Links ]
59. Montejo AL, Llorca G, Izquierdo JA. Switching to olanzapine in patients with antipsychotic-induced sexual dysfunction: a prospective and naturalistic study. Program and abstracts from the 153rd annual meeting of the American Psychiatric Association; 2000 May 13-18. Chicago; 2000. [ Links ]
60. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125-47. [ Links ]
61. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24(1):56-61. [ Links ]
62. Sandison RA, Whitelaw E, Currie JD. Clinical trials with melleril (TP21) in the treatment of schizophrenia. A two-year study. J Ment Sci. 1960;106:732-41. [ Links ]
63. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry. 1990;41(11):1238-41. [ Links ]
64. Shiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patientsa preliminary study. Acta Psychiatr Scand. 1998;98(1):81-3. [ Links ]
65. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl). 1996;124(1-2):188-96. [ Links ]
66. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(Suppl 2):109-23. [ Links ]
67. Kaplan HS. The new sex therapy. New York: Routledge; 1974. [ Links ]
68. Kane JM. Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry. 1985;46(5 Pt 2):16-21. [ Links ]
69. Gross MD. Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants. Am J Psychiatry. 1982;139(9):1193-4. [ Links ]
70. Segraves T. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry. 1989;46(3):275-84. [ Links ]
Address for correspondence:
Anna Maria Niccolai Costa
Rua Samia Haddad, 150 Apto. 142
São Paulo (SP) Brasil CEP 05709-050
Tel. (+55 11) 3749-0999 Fax (+ 55 11) 3744-5677
Sources of funding: None
Conflict of interest: Anna Maria N. Costa is a former Eli Lilly employee and currently she is a Bristol-Myers Squibb employee. Mauricio S. de Lima is an Eli Lilly employee.
Date of first submission: November 2, 2005
Last received: September 14, 2006
Accepted: September 19, 2006
Anna Maria Niccolai Costa, MD, PhD. Postgraduate from Department of Psychiatry of Universidade Federal de São Paulo; and currently medical director at Bristol-Myers Squibb Brazil, São Paulo, Brazil.
Mauricio Silva de Lima, MD, PhD. Associate professor, Department of Mental Health, Universidade Federal de Pelotas; associate professor, postgraduate course in Health and Behavior, Universidade Católica de Pelotas; investigator II-A of Brazilian Research Council (CNPq); and Medical Director at Eli Lilly Brazil, São Paulo, Brazil.
Jair de Jesus Mari, MD, PhD. Full professor, Department of Psychiatry, Universidade Federal de São Paulo; and investigator I-A, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), São Paulo, Brazil.